REG - BioPharma Credit PLC - New Investment

Biopharma CreditAnnouncement

Yesterday 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260603:nRSC8696Ga&default-theme=true

RNS Number : 8696G  BioPharma Credit PLC  03 June 2026

3 June 2026

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

NEW INVESTMENT OF UP TO US$150 MILLION IN MINERALYS THERAPEUTICS

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investment
trust, is pleased to announce that it, through its fully owned subsidiary,
together with BioPharma Credit Investments V (Master) LP ("BioPharma-V"), have
entered into a new senior secured loan agreement (the "Loan Agreement") with
Mineralys Therapeutics, Inc. ("Mineralys").  The Company will invest up to
US$150 million and BioPharma-V will invest up to an additional US$350 million
in parallel, with the Company acting as collateral agent.

 

Under the Loan Agreement, the Company will invest up to US$150 million across
four tranches, subject to customary conditions precedent:

·    Tranche A of US$30.0 million was funded at closing;

·    Tranche B of US$45 million is required to be drawn no later than 30
April 2027 upon certain regulatory approvals;

·    Tranche C of up to US$45 million is available to be drawn until 14
December 2028, subject to achievement of certain net sales milestones; and

·    Tranche D of up to US$30 million is available to be requested to be
drawn by 14 June 2029, subject to achievement of certain net sales milestones.

The loan will mature in June 2031 and will bear interest at 3-month SOFR plus
5.50 per cent. per annum subject to a 3.25 per cent. SOFR floor. An additional
one-time consideration of 2.00 per cent. of each tranche is payable by
Mineralys upon the funding of each respective tranche. Certain undisclosed
prepayment and makewhole fees, as well as exit consideration, are also payable
by Mineralys in connection with repayment of the loans.

Mineralys is a clinical-stage biopharmaceutical company focused on developing
medicines to target hypertension and related comorbidities such as chronic
kidney disease, obstructive sleep apnea and other diseases driven by
dysregulated aldosterone, with a current market capitalisation of ~US$2.5
billion (Ticker: MLYS - NASDAQ).  Its initial product candidate,
lorundrostat, is a proprietary, orally administered, highly selective
aldosterone synthase inhibitor, with an NDA currently under review with the
FDA for approval in the US.  Mineralys reported US$646.1 million in cash as
of 31 March 2026.

 

Enquiries:

 

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

 

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFVIRAIVIIR



            Copyright 2019 Regulatory News Service, all rights reserved